MedTrace Logo

Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors

NCT05071209 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2026-01-23

Study results available
· View outcomes & findings →

Summary

This phase I/II trial tests the safety, best dose, and whether elimusertib works in treating patients with solid tumors that have come back (relapsed) or does not respond to treatment (refractory). Elimusertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions

  • Recurrent Alveolar Rhabdomyosarcoma
  • Recurrent Ewing Sarcoma
  • Recurrent Lymphoma
  • Recurrent Malignant Solid Neoplasm
  • Refractory Alveolar Rhabdomyosarcoma
  • Refractory Ewing Sarcoma
  • Refractory Lymphoma
  • Refractory Malignant Solid Neoplasm

Interventions

DRUG

Elimusertib

Given PO

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Michael V Ortiz · Pediatric Early Phase Clinical Trial Network

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Months
Max Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-22
Primary Completion
2024-09-30
Completion
2026-03-31
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05071209 on ClinicalTrials.gov